Obesity leads to chronic, systemic inflammation and can lead to insulin resistance (IR), β-cell
dysfunction, and ultimately type 2 diabetes (T2D). This chronic inflammatory state …

Background The global burden of non-alcoholic fatty liver disease (NAFLD) parallels the
increase in obesity rates across the world. Although overweight and obesity status are …

Find AGA's NASH Clinical Care Pathway App for iOS and Android mobile devices at nash.
gastro. org. Scan this QR code to be taken directly to the website. Nonalcoholic fatty liver …

Nonalcoholic fatty liver disease (NAFLD) is an increasingly recognized public health
problem, affecting up to a quarter of the world's adult population. The burden of NAFLD is …

An increasing percentage of people have or are at risk to develop non-alcoholic fatty liver
disease (NAFLD) worldwide. NAFLD comprises different stadia going from isolated steatosis …

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, with an
estimated rising prevalence, in concert with the epidemics of obesity and type 2 diabetes …

Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of 25% and is a leading
cause of cirrhosis and hepatocellular carcinoma. NAFLD encompasses a disease …

Background & aims Lifestyle interventions that focus on reduced energy intake and
improved dietary pattern are the mainstay of non-alcoholic fatty liver disease (NAFLD) …

Non-alcoholic fatty liver disease (NAFLD), specifically its progressive form non-alcoholic
steatohepatitis (NASH), represents the fastest growing indication for liver transplantation in …

Alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) are the two major
types of chronic liver disease worldwide. Inflammatory processes play key roles in the …